How many times can parvovirus B19-related anemia recur in solid organ transplant recipients?

Transpl Infect Dis. 2012 Oct;14(5):E64-70. doi: 10.1111/j.1399-3062.2012.00773.x. Epub 2012 Aug 30.


Parvovirus B19 (PB19) infection is known to cause acute erythroblastopenia-mediated anemia in solid organ transplant (SOT) recipients. Intravenous immunoglobulins (IVIg) and the decrease of immunosuppression level are supposed to induce a long-term remission, although no consensus exists about the dose and the schedule of IVIg administrations. However, a few reports have shown that PB19-related anemia can recur despite this treatment, with a maximum of 3 recurrences reported. In this report, we describe in detail the cases of 2 kidney recipients with PB19 infection. They experienced, respectively, 9 and 7 PB19-related anemia recurrences. Immunosuppression level was decreased and IVIg were administered at each recurrence followed by a transitory normalization of hemoglobin level and a decrease of serum PB19 viral load. Episodes were separated by several months. These patients raise an original therapeutic management question about a frequent viral infection in SOT recipients. One patient is currently receiving IVIg every 3 months as a secondary prophylaxis without recurrence to date. These 2 case reports are followed by a review of the literature.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Anemia / etiology*
  • Anemia / prevention & control
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Kidney Transplantation / adverse effects*
  • Male
  • Parvoviridae Infections / complications*
  • Parvoviridae Infections / virology*
  • Parvovirus B19, Human / isolation & purification*
  • Recurrence


  • Immunoglobulins, Intravenous